Evolent Health (NYSE: EVH) reported Q3 EPS of ($0.04), $0.04 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $107.9 million versus the consensus estimate of $104.46 million.

For the three months ended December 31, 2017, Adjusted Revenue is expected to be in the range of $110.0 million to $112.0 million and Adjusted EBITDA is expected to be in the range of $3.0 million to $4.0 million. For the full year 2017, we expect Adjusted Revenue to be in the range of $432.0 million to $434.0 million and Adjusted EBITDA to be in the range of $(3.0) million to $(2.0) million.

For earnings history and earnings-related data on Evolent Health (EVH) click here.